The BDNF Val66Met polymorphism and plasma brain-derived neurotrophic factor levels in Han Chinese patients with bipolar disorder and schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 51, Issue , 2014, Pages 99-104

  Chen, Shiou Lan ^a,b   Lee, Sheng Yu ^b,c   Chang, Yun Hsuan ^b,d   Chen, Shih Heng ^b,f   Chu, Chun Hsien ^b,f   Wang, Tzu Yun ^b,c   Chen, Po See ^b,c   Lee, I Hui ^b,c   Yang, Yen Kuang ^b,c   Hong, Jau Shyong ^f   Lu, Ru Band ^b,c,d,e  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^f NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

BDNF Val66Met gene; Bipolar disorders; Plasma BDNF; Schizophrenia

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN; METHIONINE; VALINE;

ADULT; ANALYSIS OF VARIANCE; ASIAN CONTINENTAL ANCESTRY GROUP; BIPOLAR DISORDER; BLOOD; ETHNOLOGY; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; MALE; MIDDLE AGED; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; YOUNG ADULT;

ADULT; ANALYSIS OF VARIANCE; ASIAN CONTINENTAL ANCESTRY GROUP; BIPOLAR DISORDER; BRAIN-DERIVED NEUROTROPHIC FACTOR; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; METHIONINE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA; VALINE; YOUNG ADULT;

EID: 84893617517     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2014.01.012     Document Type: Article

References (46)

1. Alderson R.F., Alterman A.L., Barde Y.A., Lindsay R.M. Brain-derived neurotrophic factor increases survival and differentiated functions of rat septal cholinergic neurons in culture. Neuron 1990, 5:297-306.
2. Benazzi F., Akiskal H. The duration of hypomania in bipolar-II disorder in private practice: methodology and validation. J Affect Disord 2006, 96:189-196.
3. Berman J.A., Talmage D.A., Role L.W. Cholinergic circuits and signaling in the pathophysiology of schizophrenia. Int Rev Neurobiol 2007, 78:193-223.
4. Brunoni A.R., Lopes M., Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 2008, 11:1169-1180.
5. Buckley P.F., Mahadik S., Pillai A., Terry A. Neurotrophins and schizophrenia. Schizophr Res 2007, 94:1-11.
6. Buckley P.F., Pillai A., Evans D., Stirewalt E., Mahadik S. Brain derived neurotropic factor in first-episode psychosis. Schizophr Res 2007, 91:1-5.
7. Chen da C., Wang J., Wang B., Yang S.C., Zhang C.X., Zheng Y.L., et al. Decreased levels of serum brain-derived neurotrophic factor in drug-naive first-episode schizophrenia: relationship to clinical phenotypes. Psychopharmacology (Berl) 2009, 207:375-380.
8. Cirulli F., Francia N., Branchi I., Antonucci M.T., Aloe L., Suomi S.J., et al. Changes in plasma levels of BDNF and NGF reveal a gender-selective vulnerability to early adversity in rhesus macaques. Psychoneuroendocrinology 2009, 34:172-180.
9. Cunha A.B., Frey B.N., Andreazza A.C., Goi J.D., Rosa A.R., Goncalves C.A., et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett 2006, 398:215-219.
10. Daftary S.S., Calderon G., Rios M. Essential role of brain-derived neurotrophic factor in the regulation of serotonin transmission in the basolateral amygdala. Neuroscience 2012, 224:125-134.
11. Dilsaver S.C. Cholinergic mechanisms in affective disorders. Future directions for investigation. Acta Psychiatr Scand 1986, 74:312-334.
12. Driscoll I., Martin B., An Y., Maudsley S., Ferrucci L., Mattson M.P., et al. Plasma BDNF is associated with age-related white matter atrophy but not with cognitive function in older, non-demented adults. PLoS One 2012, 7:e35217.
13. Dunner D. Diagnostic revision for DSM-IV. Mania, clinical and research perspectives 1998, 3-10. American Psychiatric Press. P. Goodnick (Ed.).
14. Durany N., Michel T., Zochling R., Boissl K.W., Cruz-Sanchez F.F., Riederer P., et al. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res 2001, 52:79-86.
15. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003, 112:257-269.
16. Endicott J., Spitzer R.L. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1978, 35:837-844.
17. Fan J., Sklar P. Genetics of bipolar disorder: focus on BDNF Val66Met polymorphism. Novartis Found Symp 2008, 289:60-72. [discussion 72-63, 87-93].
18. Fernandes B.S., Gama C.S., Cereser K.M., Yatham L.N., Fries G.R., Colpo G., et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res 2011, 45:995-1004.
19. Galderisi S., Quarantelli M., Volpe U., Mucci A., Cassano G.B., Invernizzi G., et al. Patterns of structural MRI abnormalities in deficit and nondeficit schizophrenia. Schizophr Bull 2008, 34:393-401.
20. Gama C.S., Andreazza A.C., Kunz M., Berk M., Belmonte-de-Abreu P.S., Kapczinski F. Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neurosci Lett 2007, 420:45-48.
21. Gratacos M., Gonzalez J.R., Mercader J.M., de Cid R., Urretavizcaya M., Estivill X. Brain-derived neurotrophic factor Val66Met and psychiatric disorders: meta-analysis of case-control studies confirm association to substance-related disorders, eating disorders, and schizophrenia. Biol Psychiatry 2007, 61:911-922.
22. Hashim H.M., Fawzy N., Fawzi M.M., Karam R.A. Brain-derived neurotrophic factor Val66Met polymorphism and obsessive-compulsive symptoms in Egyptian schizophrenia patients. J Psychiatr Res 2012, 46:762-766.
23. Huang S.Y., Lin W.W., Ko H.C., Lee J.F., Wang T.J., Chou Y.H., et al. Possible interaction of alcohol dehydrogenase and aldehyde dehydrogenase genes with the dopamine D2 receptor gene in anxiety-depressive alcohol dependence. Alcohol Clin Exp Res 2004, 28:374-384.
24. Hyman C., Hofer M., Barde Y.A., Juhasz M., Yancopoulos G.D., Squinto S.P., et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1991, 350:230-232.
25. Iritani S., Niizato K., Nawa H., Ikeda K., Emson P.C. Immunohistochemical study of brain-derived neurotrophic factor and its receptor, TrκB, in the hippocampal formation of schizophrenic brains. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:801-807.
26. Kanazawa T., Glatt S.J., Kia-Keating B., Yoneda H., Tsuang M.T. Meta-analysis reveals no association of the Val66Met polymorphism of brain-derived neurotrophic factor with either schizophrenia or bipolar disorder. Psychiatr Genet 2007, 17:165-170.
27. Karege F., Schwald M., Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 2002, 328:261-264.
28. Laske C., Stransky E., Leyhe T., Eschweiler G.W., Wittorf A., Richartz E., et al. Stage-dependent BDNF serum concentrations in Alzheimer's disease. J Neural Transm 2006, 113:1217-1224.
29. Lu W., Zhang C., Yi Z., Li Z., Wu Z., Fang Y. Association between BDNF Val66Met polymorphism and cognitive performance in antipsychotic-naive patients with schizophrenia. J Mol Neurosci 2012, 47:505-510.
30. Mizuno K., Carnahan J., Nawa H. Brain-derived neurotrophic factor promotes differentiation of striatal GABAergic neurons. Dev Biol 1994, 165:243-256.
31. Monteleone P., Serritella C., Martiadis V., Maj M. Decreased levels of serum brain-derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders. Bipolar Disord 2008, 10:95-100.
32. Ohira K., Hayashi M. A new aspect of the TrκB signaling pathway in neural plasticity. Curr Neuropharmacol 2009, 7:276-285.
33. Pan W., Banks W.A., Fasold M.B., Bluth J., Kastin A.J. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998, 37:1553-1561.
34. Pillai A., Kale A., Joshi S., Naphade N., Raju M.S., Nasrallah H., et al. Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology. Int J Neuropsychopharmacol 2010, 13:535-539.
35. Schmidt H.D., Duman R.S. Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology 2010, 35:2378-2391.
36. Shimizu E., Hashimoto K., Watanabe H., Komatsu N., Okamura N., Koike K., et al. Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls. Neurosci Lett 2003, 351:111-114.
37. Sotiropoulou M., Mantas C., Bozidis P., Marselos M., Mavreas V., Hyphantis T., et al. BDNF serum concentrations in first psychotic episode drug-naive schizophrenic patients: associations with personality and BDNF Val66Met polymorphism. Life Sci 2013, 92:305-310.
38. Spalletta G., Morris D.W., Angelucci F., Rubino I.A., Spoletini I., Bria P., et al. BDNF Val66Met polymorphism is associated with aggressive behavior in schizophrenia. Eur Psychiatry 2010, 25:311-313.
39. Takahashi M., Shirakawa O., Toyooka K., Kitamura N., Hashimoto T., Maeda K., et al. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psychiatry 2000, 5:293-300.
40. Teh C.A., Lee T.S., Kuchibhatla M., Ashley-Koch A., Macfall J., Krishnan R., et al. Bipolar disorder, brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and brain morphology. PLoS One 2012, 7:e38469.
41. Terracciano A., Lobina M., Piras M.G., Mulas A., Cannas A., Meirelles O., et al. Neuroticism, depressive symptoms, and serum BDNF. Psychosom Med 2011, 73:638-642.
42. Toyooka K., Asama K., Watanabe Y., Muratake T., Takahashi M., Someya T., et al. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res 2002, 110:249-257.
43. Webster M.J., Weickert C.S., Herman M.M., Kleinman J.E. BDNF mRNA expression during postnatal development, maturation and aging of the human prefrontal cortex. Brain Res 2002, 139:139-150.
44. Weickert C.S., Hyde T.M., Lipska B.K., Herman M.M., Weinberger D.R., Kleinman J.E. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 2003, 8:592-610.
45. Whalley H.C., Baig B.J., Hall J., Job D.E., McIntosh A.M., Cunningham-Owens D.G., et al. Effects of the BDNF val66met polymorphism on prefrontal brain function in a population at high genetic risk of schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2010, 153B:1474-1482.
46. Zhang X.Y., Chen da C., Xiu M.H., Haile C.N., Luo X., Xu K., et al. Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls. Hum Genet 2012, 131:1187-1195.